Yahoo Web Search

Search results

1. Harpoon Therapeutics - Local Result

   • 

   • A
     Harpoon Therapeutics, Inc

     Chemical & Allied Product, Medical Laboratory

     611 Gateway Blvd, #400, South San Francisco, CA · (650) 443-7400
     
     Website
   Add or update your business

2. www.harpoontx.comHarpoon Therapeutics | Immuno-oncology | TriTAC™

   www.harpoontx.com

   • Cached

   Dec 26, 2023 · Harpoon is a biotech company developing novel biologics for cancer and other diseases using a proprietary antibody-based platform called TriTAC. TriTAC unleashes the target cell-killing properties of a patient’s own immune system by engaging T cells.

3. www.merck.com › news › merck-to-acquire-harpoonMerck to Acquire Harpoon Therapeutics, Further Diversifying ...

   www.merck.com › news › merck-to-acquire-harpoon

   • Cached

   Jan 8, 2024 · Merck and Harpoon Therapeutics announce a definitive agreement under which Merck will acquire Harpoon for $680 million. Harpoon has a portfolio of novel T-cell engagers, including HPN328, a DLL3 targeting candidate for small cell lung cancer and neuroendocrine tumors.

4. www.merck.com › news › merck-completes-acquisitionMerck Completes Acquisition of Harpoon Therapeutics, Inc.

   www.merck.com › news › merck-completes-acquisition

   • Cached

   Mar 11, 2024 · Harpoon’s lead candidate, MK-6070 (formerly known as HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors.

5. Videos

   • 

     2:37

     youtube.com

     HARP stock Harpoon Therapeutics

     Apr 3, 2023

     85 Views

   • 

     33:54

     youtube.com

     Harpoon Therapeutics, Inc. (HARP) - Is it good time to buy?

     Jun 16, 2021

     340 Views

   • 

     1:59

     finance.yahoo.com

     Merck to acquire Harpoon Therapeutics in $680M deal

     Jan 8, 2024

   View all

6. finance.yahoo.com › news › merck-completesMerck Completes Acquisition of Harpoon Therapeutics, Inc.

   finance.yahoo.com › news › merck-completes

   • Cached

   Mar 11, 2024 · Merck completes the acquisition of Harpoon, a biotech company developing T-cell engagers for cancer treatment. Harpoon's lead candidate, MK-6070, targets DLL3 in small cell lung cancer and neuroendocrine tumors.

7. harpoontx.gcs-web.comHarpoon Therapeutics | Harpoon Therapeutics, Inc.

   harpoontx.gcs-web.com

   • Cached

   Oct 23, 2023 · Harpoon Therapeutics develops T cell engagers to treat cancer and other diseases using its TriTAC, ProTriTAC and TriTAC-XR platforms. See its stock price, company profile and investor relations information.

8. www.msd.com › news › msd-completes-acquisition-ofMSD Completes Acquisition of Harpoon Therapeutics, Inc.

   www.msd.com › news › msd-completes-acquisition-of

   • Cached

   Mar 11, 2024 · MSD (Merck & Co., Inc., Rahway, N.J., USA) completes the acquisition of Harpoon Therapeutics, a biopharmaceutical company developing novel T-cell engagers for cancer. Harpoon's lead candidate, MK-6070, is a DLL3 targeting T-cell engager for small cell lung cancer and neuroendocrine tumors.

9. People also ask

   What is harpoon Therapeutics?

   • About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.

   Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology

   www.merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/

   See all results for this question

   Will Merck buy Harpoon Therapeutics?

   • Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Harpoon Therapeutics, Inc. for a price per share of $23.00 in cash. The Board of Directors of Harpoon has unanimously approved the transaction.

   Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology

   www.merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/

   See all results for this question

   What happened to harpoon Therapeutics?

   • RAHWAY, N.J., March 11, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.

   Merck Completes Acquisition of Harpoon Therapeutics, Inc. - Yahoo Fin…

   finance.yahoo.com/news/merck-completes-acquisition-harpoon-therapeutics-121500427.html

   See all results for this question

   Is harpoon a publicly traded company?

   • Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. “We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide,” said Dr. Dean Y. Li, president, Merck Research Laboratories.

   Merck Completes Acquisition of Harpoon Therapeutics, Inc

   www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/

   See all results for this question

10. www.biopharmadive.com › news › merck-harpoon-acquireMerck pays $680M for struggling cancer biotech Harpoon

    www.biopharmadive.com › news › merck-harpoon-acquire

    • Cached

    Jan 8, 2024 · Dive Brief: Merck & Co. is beefing up its cancer pipeline, announcing Monday it will pay $680 million to buy Harpoon Therapeutics for its armory of dual-acting immunotherapies targeting lung, abdominal and blood cancers. Merck agreed to pay $23 per Harpoon share, a 118% premium to the company’s $10.55 closing price Friday.